An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis

Abstract

PSORIASIS IS a chronic, inflammatory, hyperproliferative skin disorder estimated to affect up to 2.5% of the world's population.¹ Patients with psoriasis have a range of psychosocial difficulties and stresses commensurate with their physically disfiguring condition.² This psychosocial aspect of the disease is consistently underestimated and often results in suboptimal care and reduced quality of life.^3-5